Lamotrigine Extended Release
Product manufactured by Par Pharmaceutical, Inc.
Indications and Purposes
| 1 Indications And Usage Lamotrigine Extended-Release Is Indicated For: Adjunctive Therapy For Primary Generalized Tonic-Clonic Seizures And Partial-Onset Seizures With Or Without Secondary Generalization In Patients Aged 13 Years And Older. ( 1.1 ) Conversion To Monotherapy In Patients Aged 13 Years And Older With Partial-Onset Seizures Who Are Receiving Treatment With A Single Antiepileptic Drug. ( 1.2 ) Limitation Of Use: Safety And Effectiveness In Patients Younger Than 13 Years Have Not Been Established. ( 1.3 ) 1.1 Adjunctive Therapy Lamotrigine Extended-Release Is Indicated As Adjunctive Therapy For Primary Generalized Tonic-Clonic (Pgtc) Seizures And Partial-Onset Seizures With Or Without Secondary Generalization In Patients Aged 13 Years And Older. 1.2 Monotherapy Lamotrigine Extended-Release Is Indicated For Conversion To Monotherapy In Patients Aged 13 Years And Older With Partial-Onset Seizures Who Are Receiving Treatment With A Single Antiepileptic Drug (Aed). Safety And Effectiveness Of Lamotrigine Extended-Release Have Not Been Established (1) As Initial Monotherapy Or (2) For Simultaneous Conversion To Monotherapy From Two Or More Concomitant Aeds. 1.3 Limitation Of Use Safety And Effectiveness Of Lamotrigine Extended-Release For Use In Patients Younger Than 13 Years Have Not Been Established. |
All Formulated Excipients (0 Total)
None
Active Ingredients ( 1 Total)
| Name | Structure | ZINC ID(s) |
|---|---|---|
| 1. Lamotrigine |
|
ZINC13156 |